Ignite Creation Date:
2024-05-05 @ 11:30 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00060476
Status:
COMPLETED
Last Update Posted:
2017-05-09
First Post:
2003-05-06
Brief Title:
Treatment With MK0966 for the Prevention of Prostate Cancer 0966-201
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
A Double-Blind Randomized Placebo-Controlled Multicenter Study to Evaluate the Effects of Rofecoxib in Decreasing the Risk of Prostate Cancer ViP Study
Status:
COMPLETED
Status Verified Date:
2017-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine the efficacy and safety of an investigational compound MK0966 for the prevention of prostate cancer
Detailed Description:
The duration of treatment is 6 years
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2006_414 | None | None | None |
| MK0966-201 | None | None | None |
| Formally-P30A03LD | None | None | None |